Drug interactions between cisplatin and Hycamtin
| Results for the following 2 drugs: |
|---|
| cisplatin |
| Hycamtin (topotecan) |
Interactions between your selected drugs
cisplatin ↔ topotecan
Applies to:cisplatin and Hycamtin (topotecan)
MONITOR CLOSELY: Topotecan combined with a platinum agent may produce synergistic cytotoxicity against some germ cell cancers. However, myelosuppression may also be more severe. In a reported study where patients were given cisplatin 50 mg/m2 and topotecan 1.25 mg/m2/day for 5 days, one of three patients had severe neutropenia for 12 days and a second patient died with neutropenic sepsis. The interaction appears to be sequence-dependent. Specifically, coadministration of a platinum agent on day 1 of topotecan dosing required lower dosages of each agent compared to coadministration on day 5 of the topotecan dosing schedule.
MANAGEMENT: There are currently insufficient data to recommend a safe and effective regimen for topotecan in combination with a platinum agent. Clinicians should recognize the potential risk for severe neutropenia if these agents are used together, and bone marrow function must be closely monitored. Lower dosages of each agent may be required.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
